The efficacy of fluoxetine in <scp>BMS</scp>—A cross‐over study

Zoric, Bojana; Janković, Ljiljana; Pfićer, Jovana Kuzmanović; Zidverc-Trajković, Jasna; Mijajlovic, Milija; Stanimirović, Dragan

doi:10.1111/ger.12332

Cited by 11 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in patients treated with VO who reported nausea or are considered non‐responders, clinicians might consider S as a second line of treatment, and P as a third line, in relation to BMS, after a careful evaluation of the systemic comorbidities of the patient. SSRIs have shown potential in the treatment of BMS (Fleuret et al., 2014; Maina et al., 2002; Zoric et al, 2018). However, the lack of evidence of a sufficient effectiveness, combined with the methodological weaknesses of many studies, which are mainly retrospective, and the AEs associated with these drugs, has contributed to their limited use in BMS.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, in the last few years, it has not been by chance that the use of antidepressants (AD) has significantly increased in the treatment of chronic neuropathic pain (Hayashida & Obata, 2019; Xu, Zhang, & Huang, 2016) and also in BMS (Fleuret et al, 2014; Mignogna, Adamo, Schiavone, Ravel, & Fortuna, 2011; Zoric et al., 2018). Antidepressants (ADs), particularly selective serotonin reuptake inhibitors (SSRI) and selective serotonin and noradrenaline reuptake inhibitors (SNRI), are considered as central neuromodulators and have been demonstrated to be effective not only to relieve the patient's pain symptoms but also to improve any comorbid anxiety, depression, impaired sleep, and inflammation (Urits et al., 2019).…”

Section: Introductionmentioning

confidence: 99%

“…Unfortunately, until now, in the literature there have been only a few randomized controlled trials on the use of ADs in BMS, some reporting a poor therapeutic outcome (Yamazaki, Hata, Kitamori, Onodera, & Kitagawa, 2009; Zoric et al., 2018), others comparing these drugs with each other (Fleuret et al., 2014; Maina, Vitalucci, Gandolfo, & Bogetto, 2002). Recently, we have tested vortioxetine (VO), a novel multimodal antidepressant, in a pilot study in a sample of 30 patients with BMS with encouraging results, suggesting a new possibility in dentistry for the management of these patients (Adamo, Pecoraro, Aria, et al, 2020; Adamo, Pecoraro, Fortuna, et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

et al. 2020

View full text Add to dashboard Cite

Objectives This randomized open‐label trial compared the efficacy and tolerability of vortioxetine (15 mg/daily) with different antidepressants in the treatment of patients with burning mouth syndrome (BMS). Methods One and hundred fifty BMS patients were randomized into five groups and treated with either vortioxetine, paroxetine (20 mg/daily), sertraline (50 mg/daily), escitalopram (10 mg/daily) or duloxetine (60 mg/daily). The Visual Analogue Scale (VAS), Total Pain Rating Index (T‐PRI), Hamilton Rating Scales for Depression (HAM‐D) and Anxiety (HAM‐A), and Clinical Global Impression Improvement (CGI‐I) and Efficacy scales (CGI‐E) were performed at baseline and after 2, 4, 6, and 12 months of treatment. Any adverse events (AEs) were tabulated for each group. Descriptive statistics, including the Kruskal–Wallis non‐parametric test and the Friedman non‐parametric test for median comparisons between different times, were used. Results All the antidepressants (AD) were associated with a significant decrease in the VAS, T‐PRI, HAM‐A, HAM‐D, CGI‐I, and CGI‐E scores in the long‐term (p < .001). However, the response rate of the vortioxetine group showed a significant reduction after six months. The medians, after 6 months, were as follows: VAS 0.0; T‐PRI 2.0; HAM‐A 7.0; HAM‐D 7.0; CGI‐I 1.0; and CGI‐E 1.0 with a lower incidence of AEs (p < .019). Conclusion Vortioxetine was efficacious with a shorter latency of action and fewer AEs compared with other ADs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, to our surprise few randomised controlled trials (RCTs) have examined the effect of antidepressants and anxiolytics other than clonazepam on BMS symptoms . Fluoxetine was not superior to placebo in the management of pain and depression symptoms, while trazodone showed moderate effectiveness . Although some evidence from open‐label studies supports the effectiveness of commonly used antidepressants for pain remission in BMS patients, further study is required for a definitive conclusion.…”

Section: Introductionmentioning

confidence: 97%

An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives

Imamura

Shinozaki

Okada-Ogawa

et al. 2019

J of Oral Rehabilitation

View full text Add to dashboard Cite

Burning mouth syndrome (BMS) is a chronic oro-facial pain disorder of unknown cause. It is more common in peri-and post-menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS appear to be predisposed towards anxiety and depression. Atrophy of small nerve fibres in the tongue epithelium has been reported, and potential neuropathic mechanisms for BMS are now widely investigated. Historically, BMS was thought to comprise endocrinological, psychosocial and neuropathic components. Neuroprotective steroids and glial cell line-derived neurotrophic factor family ligands may have pivotal roles in the peripheral mechanisms associated with atrophy of small nerve fibres. Denervation of chorda tympani nerve fibres that innervate fungiform buds leads to alternative trigeminal innervation, which results in dysgeusia and burning pain when eating hot foods. With regard to the central mechanism of BMS, depletion of neuroprotective steroids alters the brain network-related mood and pain modulation. Peripheral mechanistic studies support the use of topical clonazepam and capsaicin for the management of BMS, and some evidence supports the use of cognitive behavioural therapy. Hormone replacement therapy may address the causes of BMS, although adverse effects prevent its use as a first-line treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may have important benefits, and well-designed controlled studies are expected. Other treatment options to be investigated include brain stimulation and TSPO (translocator protein 18 kDa) ligands. K E Y W O R D Sburning mouth syndrome, central pain modulation, menopause, neuroprotective steroids | 575 IMAMURA et Al. | INTRODUC TI ONBurning mouth symptoms that occurred as secondary phenomena attributable to local conditions 1-9 were previously referred to as "secondary" burning mouth syndrome (BMS), 10 but BMS now refers only to burning symptoms not attributable to local or systemic causes. 11 After excluding such conditions, some common characteristics of BMS are important. Burning sensations are usually bilateral, and intensity fluctuates. 2 The most common site is the tip of the tongue, but pain is often noted at the lateral border of the tongue, lips and hard palate. 12 Affected persons often complain of dysgeusia, 13 which may be accompanied by subjective xerostomia. 14 Peri-and post-menopausal women are predisposed to the condition.Some patients exhibit depressive symptoms and anxiety 15-18 and may express concern regarding the presence of a malignant condition. 10,16 Psychosocial stressors can trigger or worsen pain, 15,19 while eating and drinking usually alleviate pain. 10,20 These manifestations are characteristic features of BMS and should not be excluded as secondary signs or symptoms of primary disease. Agreement on these clinical features yields important clues in understanding the underlying pathoph...

show abstract

“…In fact, fluoxetine was able to increase neurogenesis and survival in three-month-old mice, but not in older mice [ 78 , 79 ]. This evidence might imply that in the elderly population, the antidepressant effect of SSRI, which is still present, might involve other mechanisms besides neurogenesis [ 80 ]. Conversely, if we consider the large variability of the number of neural precursors in the general population, especially in the elderly, one can speculate that this can be a relevant factor influencing the response to antidepressants [ 7 ].…”

Section: Pharmacological Treatments and Ahn In Animal Models And Humansmentioning

confidence: 99%

Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?

Carli

Aringhieri

Kolachalam

et al. 2021

View full text Add to dashboard Cite

: Adult neurogenesis consists in the generation of newborn neurons from neural stem cells taking place in the adult brain. In mammals, this process is limited to very few areas of the brain, and one of these neurogenic niches is the subgranular layer of the dentate gyrus (DG) of the hippocampus. Adult newborn neurons are generated from quiescent neural progenitors (QNPs), which differentiate through different steps into mature granule cells (GCs), to be finally integrated into the existing hippocampal circuitry. In animal models, adult hippocampal neurogenesis (AHN) is relevant for pattern discrimination, cognitive flexibility, emotional processing and resilience to stressful situations. Imaging techniques allow to visualize newborn neurons within the hippocampus through all their stages of development and differentiation. In humans, the evidence of AHN is more challenging, and, based on recent findings, it persists through the adulthood, even if it declines with age. Whether this process has an important role in human brain function and how it integrates into the existing hippocampal circuitry is still a matter of exciting debate. Importantly, AHN deficiency has been proposed to be relevant in many psychiatric disorders, including mood disorders, anxiety, post-traumatic stress disorder and schizophrenia. This review aims to investigate how AHN is altered in different psychiatric conditions and how pharmacological treatments can rescue this process. In fact, many psychoactive drugs, such as antidepressants, mood stabilizers and atypical antipsychotics (AAPs), can boost AHN with different results. In addition, some non-pharmacological approaches are discussed as well.

show abstract

The efficacy of fluoxetine in BMS—A cross‐over study

Abstract: Our trial results indicate that fluoxetine therapy not only improves the psychological status of participants with BMS but also fluoxetine decreases the intensity of pain in these patients.

Cited by 11 publications

References 25 publications

Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives

Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?

Contact Info

Product

Resources

About